Genentech's Giredestrant Shows Promise in Reducing Breast Cancer Recurrence Risk
Genentech, a member of the Roche Group, has announced promising results from its Phase III lidERA Breast Cancer study. The study evaluated the efficacy of giredestrant, an investigational oral selective estrogen receptor degrader (SERD), as an adjuvant endocrine treatment for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, early-stage breast cancer. The interim analysis revealed that giredestrant significantly reduced the risk of invasive disease recurrence or death by 30% compared to standard-of-care endocrine therapy. This marks a significant advancement in endocrine therapy, the first in over 20 years, for early-stage ER-positive breast cancer, which accounts for approximately 70% of breast cancer cases. The results were presented at the 2025 San Antonio Breast Cancer Symposium. 
